Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
8th grade Good
|
New words:
accrual, actuarially, Advisory, Alabama, antipsychotic, antitrust, APBO, borrowing, calculation, case, Central, Chugai, cisplatin, construction, county, customer, emotional, entitled, estrogen, exenatide, financed, greater, healthcare, incretin, inhibitor, Japanese, Jersey, Medicaid, Minnesota, modulator, monetary, monotherapy, norepinepherine, older, Oncologic, overpaid, physical, Pipeline, procedural, Public, rebate, receptor, reclassified, redemption, relief, remeasured, restated, retroactively, reuptake, Rockland, routine, Select, selective, serotonin, Similarly, sponsor, stayed, sued, Suffolk, treble, violated, Westchester
Filing tables
Filing exhibits
- 10-Q Quarterly report
- 10.1 Deferred Compensation Plan
- 10.2 Change In Control Severance Pay Plan
- 10.3 2007 Change In Control Severance Pay Plan
- 11 Statement Re: Computation of Earnings Per Share
- 12 Statement Re: Computation of Ratio of Earnings
- 31.1 302 Certification of Chief Executive Officer
- 31.2 302 Certification of Chief Financial Officer
- 32 906 Certification of CEO and CFO
- 99.1 Cautionary Statement
LLY similar filings
Filing view
External links
EXHIBIT 11. STATEMENT RE: COMPUTATION OF EARNINGS PER SHARE
(Unaudited)
Eli Lilly and Company and Subsidiaries
Three Months Ended | Six Months Ended | |||||||||||||||
June 30, | June 30, | |||||||||||||||
2004 | 2003 | 2004 | 2003 | |||||||||||||
(Dollars and shares in millions except per- share data) | ||||||||||||||||
BASIC | ||||||||||||||||
Net income | $ | 656.9 | $ | 692.2 | $ | 1,057.3 | $ | 1,099.2 | ||||||||
Average number of common shares outstanding | 1,083.9 | 1,076.8 | 1,082.1 | 1,076.4 | ||||||||||||
Basic earnings per share | $ | .61 | $ | .64 | $ | .98 | $ | 1.02 | ||||||||
DILUTED | ||||||||||||||||
Net income | $ | 656.9 | $ | 692.2 | $ | 1,057.3 | $ | 1,099.2 | ||||||||
Average number of common shares outstanding | 1,083.9 | 1,076.8 | 1,082.1 | 1,076.4 | ||||||||||||
Incremental shares – stock options | 6.8 | 5.6 | 6.8 | 5.8 | ||||||||||||
Adjusted average shares | 1,090.7 | 1,082.4 | 1,088.9 | 1,082.2 | ||||||||||||
Diluted earnings per share | $ | .60 | $ | .64 | $ | .97 | $ | 1.02 | ||||||||